Navigation Links
China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
Date:3/31/2008

KUNMING, China, March 31 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN) ("China Shenghuo" or "the Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced it will conduct a conference call at 8:00 a.m. EDT on Wednesday, April 2, 2008, to discuss the Company's financial results for the fiscal year ended December 31, 2007.

Hosting the call will be Mr. Feng Lan, President, and Ms. Qionghua Gao, Chief Financial Officer.

To participate in the event by telephone, please dial (800) 638-4930 five to 10 minutes prior to the start time (to allow time for registration) and reference the conference ID 28825392. International callers should dial (617) 614-3944 and reference the same passcode.

A digital replay of the call will be available on Wednesday, April 2 at approximately 10:00 a.m. EDT through Wednesday, April 9 at 12 p.m. EDT. To listen to the replay, dial (888) 286-8010 and enter the conference ID number 63812946. International callers should dial (617) 801-6888 and enter the same conference ID number.

The conference call will also be webcast live over the Internet and can be accessed by all interested parties at the company's Web site: http://www.shenghuo.com.cn.

To monitor the live webcast, please visit the Company's Web site and click on the webcast link at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. An audio replay of the event will be archived on China Shenghuo's Web site.

About China Shenghuo Pharmaceutical Holdings, Inc.

Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, the company's reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company's intellectual property rights, market acceptance of the company's products, changes in the laws of the People's Republic of China that affect the company's operations, the company's ability to obtain all necessary government certifications and/or licenses to open and operate retail specialty counters to offer its cosmetic products and conduct the company's business, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company's operations and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

China Shenghuo Pharmaceutical Holdings, Inc

Ms. Gao Qionghua, CFO

Tel: +86-871-7282608

Email: qionghua_kmsh@163.com

CCG Elite Investor Relations

Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour
2. China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
3. China Yingxia International Announces Soybean Milk Production Lines Acquisition
4. Cells from the Research Institute of the MUHC on the road to China
5. China Medicine Announces Record Fourth Quarter and Fiscal Year 2007 Results
6. China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call
7. China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
8. China RuiTai International Holdings Retains CCG Elite for Investor Relations Services
9. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
10. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
11. China Nepstar Chain Drugstore Announces Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: